COLL - Market Is Turning A Blind Eye To Collegium's Lack Of Debt And Opioid Lawsuits
Image Source: SciTech Daily
Company Thesis
Collegium's (COLL) abuse deterrent Xtampza indicated for acute relief of chronic pain is now the exclusive ER oxycodone for nearly 40% of commercially insured Americans. This is a welcoming development considering there are currently no alternatives for the alleviation of chronic pain aside from opiates, which are by nature addictive and prone to abuse. Considering the company did not market opioids during the height of the opiate epidemic (2006-2012), its lack of debt obligations, and solid financial strength from its ability to organically grow prescriptions of Xtampza,